Vol. 9, Issue 10 (2020)
The role of fluoroquinolones for the treatment of brucellosis: An overview
Arijit Shil, Dr. Paramita Dey and Dr. Tapan Kumar Mandal
The gram negative, non motile, intercellular bacterium is the Brucella bacterium which is named after the micro-biologist, David Bruce. Globally, brucellosis is a common zoonotic infection caused by the genus Brucella, which is transmitted to human from infected animals especially goats, sheep, and cattle. It is an ancient condition linked to the consumption of fluid-derived products, such as unpasteurized milk and milk products. As a systemic disease, it can affect any host body organ or organ system. Human brucellosis exhibits multiple clinical signs and making it difficult to diagnose. Therapeutic options for brucellosis are predominantly based on uncontrolled, non-randomized, non-blinded trials. Brucella sp. changes the level of pH in the intracellular environment and the first approach for the treatment is to prescribe antibiotics that have an acidic activity. Although anti-brucellosis treatment regimens include quinolones (fluoroquinolone) which are remarkable drug which may be able to act intracellularly under acidic conditions. So, the present review has undertaken to evaluate the efficacy, safety, and patient tolerability of fluoroquinolone regimens Based on the outcomes, the potential role of fluoroquinolone as an anti-brucellosis has been established.